Biologic Paired Thermosensitive Drug Delivery Platform for IBD 

Topical Delivery of IL-10 Using a Thermosensitive Drug Delivery Platform to Treat Murine Colitis

There is still no completely effective treatment for inflammatory bowel disease. Current therapies usually involve giving patients costly and sometimes dangerous systemic treatments (treatments that are untargeted and can adversely affect the entire body) or localized therapies, which are constrained by current enema mechanics. Dr. Sidhartha Sinha at the Stanford University School of Medicine created an FDA approved drug platform called TDP that is liquid at room temperature and a viscous gel at body temperature. After discovering that TDP increases the effectiveness of current clinical IBD therapeutics, we wanted to explore new applications of this technology with its new capability for truly localized treatment in mind. By pairing a very small concentration of IL-10, an effective anti-inflammatory protein that our bodies naturally produce, with our thermosensitive drug delivery platform, we were able to create a more effective, safe, and low-cost alternative therapeutic option for inflammatory bowel disease.

Research study presented by Anika Ullah, a coauthor of the study, at Digestive Disease Week 2017. The study received a poster of distinction award by the American Gastroenterological Association (AGA) for ranking in the 10% of all submitted abstracts to the AGA. 

I was selected as the only current undergraduate student in the nation to receive a 2017 Student Abstract Prize from the AGA for outstanding scientific work.

Publication in progress.

Publication of Abstract

Sinha, Sidhartha R., Linh Nguyen, Anika N. Ullah, and Aida Habtezion. "Topical Delivery of IL-10 Using a Thermosensitive Drug Delivery Platform to Treat Murine Colitis." Gastroenterology 152, no. 5 (2017): S567.